Maria Claudia Costa

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Transcription Factor

Bioinformatics Analysis

Top Venues

Journal of translational medicine

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Maria Claudia Costa, Claudia Angelini, Monica Franzese, Concetta Iside, Marco Salvatore, Luigi Laezza, Francesco Napolitano, Michele Ceccarelli
Identification of therapeutic targets in osteoarthritis by combining heterogeneous transcriptional datasets, drug-induced expression profiles, and known drug-target interactions. Journal of translational medicine 22 (1) (2024)
Maria Claudia Costa, Claudia Angelini, Monica Franzese, Concetta Iside, Marco Salvatore, Luigi Laezza, Francesco Napolitano, Michele Ceccarelli
Identification of therapeutic targets in osteoarthritis by combining heterogeneous transcriptional datasets, drug-induced expression profiles, and known drug-target interactions. Journal of translational medicine 22 (1) (2024)
Maria Claudia Costa, Claudia Angelini, Monica Franzese, Concetta Iside, Marco Salvatore, Luigi Laezza, Francesco Napolitano, Michele Ceccarelli
Identification of therapeutic targets in osteoarthritis by combining heterogeneous transcriptional datasets, drug-induced expression profiles, and known drug-target interactions. Journal of translational medicine 22 (1) (2024)
Maria Claudia Costa, Claudia Angelini, Monica Franzese, Concetta Iside, Marco Salvatore, Luigi Laezza, Francesco Napolitano, Michele Ceccarelli
Identification of therapeutic targets in osteoarthritis by combining heterogeneous transcriptional datasets, drug-induced expression profiles, and known drug-target interactions. Journal of translational medicine 22 (1) (2024)
Teresa Maria Rosaria Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Roberta Mortarini, Giovanni Scala, Maria Claudia Costa, Sandra Coral, Wolf Herman Fridman, Catherine Sautès-Fridman, Silvia Brich, Giancarlo Pruneri, Elena Simonetti, Maria Fortunata Lofiego, Rossella Tufano, Davide Bedognetti, Alessandro Desideri, Michele Maio, Michele Ceccarelli
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. Nature communications 14 (1) (2023)